Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EYENYSE:GKOSNASDAQ:IRTCNASDAQ:NARI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEYENational Vision$21.02+0.0%$15.61$9.56▼$21.73$1.66B1.241.85 million shs1.53 million shsGKOSGlaukos$95.68+1.1%$91.90$77.10▼$163.71$5.47B0.8713,496 shs778,321 shsIRTCiRhythm Technologies$148.53+0.7%$124.01$55.92▼$150.00$4.74B1.4482,313 shs402,263 shsNARIInari Medical$79.97$79.97$39.76▼$79.99$4.68B1.021.36 million shsN/A10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEYENational Vision+0.05%-1.41%+22.42%+76.49%+46.69%GKOSGlaukos+1.20%+1.18%+6.38%-7.23%-15.24%IRTCiRhythm Technologies+0.71%+2.45%+7.86%+46.06%+56.13%NARIInari Medical0.00%0.00%0.00%0.00%+72.27%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEYENational Vision3.2585 of 5 stars2.24.00.03.33.40.80.0GKOSGlaukos4.5725 of 5 stars4.43.00.04.41.42.50.6IRTCiRhythm Technologies1.1186 of 5 stars2.53.00.00.01.50.00.6NARIInari Medical0.2473 of 5 stars1.10.00.00.00.02.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEYENational Vision 2.44Hold$17.75-15.56% DownsideGKOSGlaukos 2.75Moderate Buy$134.6740.75% UpsideIRTCiRhythm Technologies 2.91Moderate Buy$133.73-9.97% DownsideNARIInari Medical 2.14Hold$69.22-13.44% DownsideCurrent Analyst Ratings BreakdownLatest EYE, GKOS, NARI, and IRTC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025IRTCiRhythm TechnologiesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$130.00 ➝ $167.005/19/2025EYENational VisionBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetMarket Perform ➝ Market Perform$13.00 ➝ $19.005/12/2025EYENational VisionBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$14.00 ➝ $17.005/9/2025EYENational VisionThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$13.00 ➝ $17.005/9/2025EYENational VisionCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$13.00 ➝ $21.005/8/2025EYENational VisionUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$18.00 ➝ $20.005/8/2025EYENational VisionLoop CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$18.00 ➝ $20.005/8/2025EYENational VisionWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$13.00 ➝ $15.005/7/2025EYENational VisionBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeUnderperform ➝ Buy5/6/2025GKOSGlaukosMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$110.00 ➝ $72.005/2/2025GKOSGlaukosStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$140.00 ➝ $115.00(Data available from 6/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEYENational Vision$1.85B0.90$2.99 per share7.03$10.60 per share1.98GKOSGlaukos$404.52M13.52N/AN/A$9.46 per share10.11IRTCiRhythm Technologies$618.59M7.67N/AN/A$6.85 per share21.68NARIInari Medical$493.63M9.48$0.09 per share906.95$8.07 per share9.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEYENational Vision-$65.90M-$0.33N/A77.853.27-0.81%3.52%1.39%8/6/2025 (Estimated)GKOSGlaukos-$134.66M-$2.37N/AN/AN/A-39.04%-16.53%-10.61%7/30/2025 (Estimated)IRTCiRhythm Technologies-$123.41M-$3.14N/AN/AN/A-19.14%-118.83%-11.34%7/30/2025 (Estimated)NARIInari Medical-$1.64M-$1.35N/A727.00N/A-13.68%-10.09%-6.60%N/ALatest EYE, GKOS, NARI, and IRTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025EYENational Vision$0.32$0.34+$0.02$0.18$510.30 million$510.32 million5/1/2025Q1 2025IRTCiRhythm Technologies-$0.89-$0.95-$0.06-$0.97$153.39 million$158.68 million4/30/2025Q1 2025GKOSGlaukos-$0.33-$0.22+$0.11-$0.32$102.78 million$106.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEYENational VisionN/AN/AN/AN/AN/AGKOSGlaukosN/AN/AN/AN/AN/AIRTCiRhythm TechnologiesN/AN/AN/AN/AN/ANARIInari MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEYENational Vision0.300.570.37GKOSGlaukos0.195.544.71IRTCiRhythm Technologies9.006.276.12NARIInari MedicalN/A1.771.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEYENational VisionN/AGKOSGlaukos99.04%IRTCiRhythm TechnologiesN/ANARIInari Medical90.98%Insider OwnershipCompanyInsider OwnershipEYENational Vision2.70%GKOSGlaukos5.80%IRTCiRhythm Technologies1.10%NARIInari Medical10.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEYENational Vision14,00079.05 million76.94 millionOptionableGKOSGlaukos78057.14 million51.61 millionOptionableIRTCiRhythm Technologies1,79031.93 million31.09 millionOptionableNARIInari Medical80058.54 million52.34 millionOptionableEYE, GKOS, NARI, and IRTC HeadlinesRecent News About These CompaniesAmerican Century Small Cap Growth Fund Q1 2025 CommentaryJune 11 at 5:48 AM | seekingalpha.comThrombectomy system removes clots, improves quality of life for patients with PEMay 20, 2025 | healio.comThe top nitinol cardiac medtech news of 2025 (so far)May 13, 2025 | medicaldesignandoutsourcing.comStryker outlines 2025 growth targets with 8.5%-9.5% organic sales growth and $13.20-$13.45 EPSMay 2, 2025 | msn.comExpert Testimony Supporting POPR Can Be An Effective StrategyApril 21, 2025 | jdsupra.comVolta Medical Appoints Bill Hoffman as Executive Chairman of the Board of DirectorsApril 8, 2025 | finance.yahoo.com8 spine, orthopedic acquisitions in Q1March 27, 2025 | beckersspine.comOkami Medical Announces Portfolio Expansion with the Addition of the SENDERO® MAX Delivery CatheterMarch 26, 2025 | finance.yahoo.comHow Is Inari Medical Inc. (NASDAQ:NARI) Positioned in the Medical Devices Sector?March 25, 2025 | kalkinemedia.comIf You Could Only Hold 3 Investments for Life, Consider These (NARI)March 10, 2025 | marketbeat.comStryker’s Inari Medical Launches Artix Thrombectomy SystemMarch 7, 2025 | evtoday.comStryker’s Inari Medical launches Artex thrombectomy systemMarch 7, 2025 | massdevice.comInari Medical introduces thrombectomy system for arterial thrombus casesMarch 7, 2025 | msn.comInari Medical acquisition could provide Stryker with foothold in peripheral vascular marketFebruary 28, 2025 | expresshealthcare.inWearable defibrillator maker Kestra Medical plots $150M IPOFebruary 26, 2025 | fiercebiotech.comStryker grows cardiovascular division with Inari Medical acquisitionFebruary 24, 2025 | medicaldevice-network.comStryker Completes Acquisition of InariFebruary 20, 2025 | evtoday.comStryker concludes Inari Medical acquisition for $4.9bnFebruary 20, 2025 | finance.yahoo.comStryker completes Inari Medical acquisitionFebruary 20, 2025 | beckersspine.comInari Medical, Inc. (NARI): the Best Performing Healthcare Stock So Far in 2025February 20, 2025 | msn.comStryker completes acquisition of Inari MedicalFebruary 19, 2025 | massdevice.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBuybacks and Big-Time Developments: 3 Stocks Making Huge MovesBy Leo Miller | May 19, 2025View Buybacks and Big-Time Developments: 3 Stocks Making Huge MovesThese 3 Stocks Are Buying Back Billions in SharesBy Leo Miller | June 3, 2025View These 3 Stocks Are Buying Back Billions in SharesViking Holdings Posts Strong Q1, Eyes Growth AheadBy Chris Markoch | May 20, 2025View Viking Holdings Posts Strong Q1, Eyes Growth AheadCisco Stock Eyes New Highs in 2025 on AI, Earnings, UpgradesBy Thomas Hughes | May 16, 2025View Cisco Stock Eyes New Highs in 2025 on AI, Earnings, UpgradesKeep Your EYE on This Stock, It Just Got a Rare Double UpgradeBy Sam Quirke | May 15, 2025View Keep Your EYE on This Stock, It Just Got a Rare Double UpgradeEYE, GKOS, NARI, and IRTC Company DescriptionsNational Vision NASDAQ:EYE$21.02 +0.01 (+0.05%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$21.10 +0.09 (+0.40%) As of 04:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.National Vision Holdings, Inc., through its subsidiaries, operates as an optical retailer in the United States. The company operates in two segments, Owned & Host and Legacy. It offers eyeglasses and contact lenses, and optical accessory products; provides eye exams through its America's Best, Eyeglass World, Vista Optical, Fred Meyer, and Vista Optical military, as well as Vision Center branded stores; and offers health maintenance organization and optometric services. National Vision Holdings, Inc. was founded in 1990 and is headquartered in Duluth, Georgia.Glaukos NYSE:GKOS$95.68 +1.04 (+1.10%) Closing price 06/10/2025 03:59 PM EasternExtended Trading$95.88 +0.20 (+0.21%) As of 07:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.iRhythm Technologies NASDAQ:IRTC$148.53 +1.05 (+0.71%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$144.49 -4.04 (-2.72%) As of 06/10/2025 04:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.Inari Medical NASDAQ:NARI$79.97 0.00 (0.00%) As of 02/19/2025Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike Stock Hits All-Time Highs: Smart Buy or FOMO Trap? These 3 Stocks Could Be Back in Play Before You Know It Casey’s Surges on Strong Q4, More Gains Likely Ahead Qualcomm: What Monday’s Jump Tells Us About the Stock's Prospects D-Wave Is Soaring—But Is ETF Diversification the Better Strategy? Government Mandate Sends eVTOL Stocks Flying AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway Meta Pulls Ahead of the Mag 7: Analysts Predict a Breakout Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
